Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03422536
Title Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Arizona

auditory system cancer

lip cancer

paranasal sinus cancer

nasopharynx carcinoma

head and neck squamous cell carcinoma



Cetuximab + Ficlatuzumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.